Goldman Sachs Lowers Price Target On Genzyme (GENZ); Maintains Sell
GENZ Hot Sheet
Rating Summary:1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 25 | Down: 12 | New: 36
Goldman Sachs transfers coverage on Genzyme Corp. (Nasdaq: GENZ), maintaining a Sell rating and lowered their price target from $63 to $60. The new analyst cited no back-up manufacturing for Cerezyme and Fabrazyme, Lumizyme approval could further strain capacity, possible change in reimbursement from a health care reform bill.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
You May Also Be Interested In
- BMO Capital on NetApp (NTAP): Could Attract Interested Parties At These Levels; Prefers EMC
- Auriga Cuts PT and Estimates on HEICO (HEI); Cautious on Decelerating FSG Growth
- Little Room to Move for Shares of Newmont Mining (NEM)
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
